Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Stoke Therapeutics ( (STOK) ) is now available.
On February 14, 2025, Stoke Therapeutics entered into a License and Collaboration Agreement with Biogen for the development and commercialization of zorevunersen, a potential first-in-class treatment for Dravet syndrome. Biogen receives exclusive commercialization rights outside the US, Canada, and Mexico, while Stoke will receive $165 million upfront with potential for milestone payments up to $385 million. This collaboration aims to advance zorevunersen to Phase 3 with an expected data readout in late 2027, and funds from Biogen are projected to support Stoke’s operations through mid-2028. The partnership underscores Biogen’s strategy to expand its rare disease pipeline and Stoke’s commitment to developing treatments for genetic disorders, potentially providing significant treatment advances for patients with Dravet syndrome.
More about Stoke Therapeutics
Stoke Therapeutics is a biotechnology company specializing in RNA medicine, focusing on diseases of the central nervous system and the eye caused by a loss of about 50% of normal protein levels. The company is developing antisense oligonucleotides to restore protein expression and has its headquarters in Bedford, Massachusetts.
YTD Price Performance: -5.24%
Average Trading Volume: 738,882
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $565.7M
For a thorough assessment of STOK stock, go to TipRanks’ Stock Analysis page.
